Feds clamp a hold on Forum’s PhIII Alzheimer’s study following GI events

John Carroll

The FDA has slammed the brakes on the late-stage Alzheimer's development program for encenicline after investigators reported a "small" number of serious gastrointestinal adverse among patients taking the drug, the lead therapy for Waltham, MA-based Forum Pharmaceuticals.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS